- Sarepta Therapeutics, Inc. stock price today and history
Sarepta Therapeutics, Inc. (SRPT) stock prices updated...
Please, Signup (Login) to subscribe or trade (demo)
Sarepta Therapeutics, Inc. stock price
Sarepta Therapeutics, Inc. latest news:
BRIEF-Sarepta Therapeutics says exercise of option to purchase additional convertible senior notes due 2024
* SAREPTA THERAPEUTICS ANNOUNCES EXERCISE OF INITIAL
OPTION TO PURCHASE ADDITIONAL CONVERTIBLE SENIOR NOTES DUE 2024
Source text for Eikon:
Further company coverage:
BRIEF-Sarepta Therapeutics announces proposed offering of $375 mln of convertible senior notes
Sarepta Therapeutics Inc(SRPT). * Sarepta Therapeutics(SRPT) announces proposed offering of $375 million of convertible senior notes due 2024.
Sarepta Therapeutics shares dive on safety issues in FDA database
Sarepta Therapeutics Inc. shares declined as much as 8% in morning trade Friday on safety issues reported in the Food and Drug Administration's Adverse Events Reporting System (FAERS) for the company's controversial Exondys 51 therapy. The FAERS database showed 13 serious events connected to the Duchenne muscular dystrophy therapy, including three patient deaths. But "we believe these reported issues are generally expected outcomes of a progressive fatal disease like DMD and are not necessarily due to any mechanistic or safety flaws of the drug itself," said Leerink Partners analyst Joseph Schwartz. Company management told Leerink that the reported deaths happened in patients late in the disease, towards the end of their lives, according to Schwartz. FAERS, which the FDA recently made more accessible and user-friendly, "while insightful, requires a bit more diligence for full interpretation," Schwartz said. Sarepta did not immediately return MarketWatch's request for comment. Shares were most recently down 2.9%. Shares have surged 37.2% over the last three months, compared with a 4% rise in the S&P 500 .Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
PTC Therapeutics gains after FDA panel votes against drug approval
PTC Therapeutics Inc. stock gained 10% in after-hours action Thursday after trading was halted for the entire regular session as a Food and Drug Administration panel discussed the company's Duchenne muscular dystrophy drug. The panel eventually voted not to approve the drug, saying that more testing was required to prove its efficacy, though they did not completely reject the drug. The FDA does not have to follow the panel's recommendation, as it showed in controversially approving a drug for the same disease last year from Sarepta Therapeutics Inc. despite a panel recommendation against the approval. After being halted at Wednesday's closing price of $17.46 all day, PTC shares resumed trading just before 6 p.m. Eastern time Thursday and topped $19.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
SB Financial Group, Inc.SBFG
SB Financial Group, Inc.SBFGP
SBA Communications CorporationSBAC
Schmitt Industries, Inc.SMIT
Schnitzer Steel Industries, Inc.SCHN
SciClone Pharmaceuticals, Inc.SCLN
Scientific Games CorpSGMS